Roni Lara Moya, BMD, PhD
- Intravenous Antioxidants, Laetrile and Artesunate as Integrative Treatment in Oncology
Intravenous Antioxidants, Laetrile and Artesunate as Integrative Treatment in Oncology Cancer is a major threat to human health, but the currently available cancer chemotherapy regimens may result in several critical problems, including insufficient effectiveness, serious adverse effects and the development of multidrug resistance. Thus, more effective treatments that result from the discovery of new anticancer agents to resolve these problems would be highly desirable. There is now growing evidence that the mitochondria might be primary targets in cancer therapeutics instead of simple bystanders during cancer development. This cancer‐specific metabolic remodeling can be reversed by dichloro‐acetate (DCA), a mitochondria‐targeting small molecule that penetrates most tissues after oral or injectable administration. The preclinical work on DCA (showing effectiveness in a variety of tumors and relatively low toxicity) Moreover, Artesunate derived from artemisinin, which is extracted from Artemisia annua L. is a widely used antimalarial agent with a remarkable broad anti‐cancer activity. Artemisinins have demonstrated cytotoxic effects against a variety of cancer cells by inducing cell cycle arrest, promoting apoptosis, preventing angiogenesis, and abrogating cancer invasion and metastasis. Furthermore, the vitamin B17, also known by laetrile, is derived from laevorotatory and mandelonitrile and is used to describe a purified form of the chemical amygdalin, a cyanogenic glucoside (a plant compound that contains sugar and produces hydrogen cyanide) found in the pits of many fruits and raw nuts and in other plants, such as lima beans, clover, and sorghum. Hydrogen cyanide is thought to be the main anticancer compound formed from laetrile via in situ release. Laetrile has been used for cancer treatment both as a single agent and in combination with a symbiotic cell therapy program that consists of a specialized anti‐aging cell activation complex of vitamins, amino acids and mitochondrial modulators such as acetyl cysteine, L‐carnitine, taurine, lysine, arginine, B complex, magnesium, vitamin C, etc. As far as other antioxidants, alpha lipoic acid (ALA) is characterized as a strong water and fat‐soluble antioxidant, and is known as a human “natural antioxidant”. ALA, a member of the B vitamin family is a coenzyme in the multienzyme complexes of dehydrogenase and aminocaproic acid decarboxylase. Recent research confirmed that ALA can inhibit cancer cell proliferation in cervical cancer and colon cancer. Finally, since 1970, Linus Pauling established that the C‐Vitamin could potentially and selectively kill tumors by the induction of the hydrogen peroxide in the malignant cells, but not in the healthy cells. Nowadays, more scientific studies have been published concerning the use of intravenous antioxidants to combat cancer, such as alpha lipoic acid, complex B, selenium, glutathione, cysteine, magnesium, zinc and high‐dose of vitamin C as a potential chemotherapeutic agents for cancer treatment. The actual scientific data, combined with the clinical practice, show positive results when the intravenous nutrition is applied integrated with the chemotherapy or radiotherapy conventional protocols. Most of all, they may be developed to increase patient’s quality of life and reduce the hard pharmaceuticals or radiation side effects, such as nausea, dizziness, anemia, fatigue, immune suppression and pain. The aim of this talk is to discuss the best and safest nutritional protocols in integrative intravenous oncology and the possible anti‐cancer mechanisms behind.
Biomedicine ‐ University of Mogi das Cruzes, Sao Paulo. Specialization in Anti‐Aging Medicine – Seville University, Spain Master Science in Molecular and Cellular Immunology and Biology – University of Coimbra, Portugal Master Science in Clinical Advanced Nutrition – University of Barcelona, Spain PhD in Biomedicine and Immunology – Gulbenkian Institute of Science and Coimbra University. Coordinator of Orthomolecular Medicine of ReGenera Research Group for Aging Intervention Professor and Director of the Graduation Program in Orthomolecular Therapy ‐ CESPU University, Portugal. Scientific Advisor for Nutraceuticals and Cell Therapy Companies in Europe